ERBB2 and breast carcinoma: In summary, we screened a series of mouse- and rabbit-derived antibodies against human HER2 and identified r40 as an ECD III/IV-specific antibody that disrupted PI3K/AKT and MAPK signaling pathways and suppressed the growth of breast cancer cells.